The Zhitong Finance App learned that according to Hong Kong Stock Exchange documents, the world's leading AI-driven biotechnology company Insisilicon Smart has once again submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as co-sponsors.

Insilicon Smart's business model includes pipeline drug development, drug discovery services, and software solution services. The company's core product ISM001-055 is a small molecule drug candidate that mainly treats fibrosis-related indications by inhibiting TRAF2 and NCK interacting protein kinase (TNIK) (a newly discovered anti-fibrosis target). As of the last practical date, the company has 15 drug candidate pipelines covering fibrosis, oncology, immunology and other treatment fields, 6 of which have obtained IND approval for clinical trials.

According to the prospectus, the company's revenue for 2022 and 2023 was US$30.147 million and US$51.18 million, respectively; adjusted losses (non-IFRS measures) of US$70.8 million and US$67.4 million were recorded, respectively.